Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest

Gynecologic Oncology

Volumn 100, Issue 3, 2006, Pages 487-494

  Bae Jump, Victoria L ^a   Zhou, Chunxiao ^a   Gehrig, Paola A ^a   Whang, Young E ^a   Boggess, John F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; Cervical cancer; Ovarian cancer; Rapamycin; Telomerase

Indexed keywords

DNA FRAGMENT; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN S6; RAPAMYCIN; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; HUMANS; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TELOMERASE;

EID: 32644476664     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.053     Document Type: Article

References (38)

1. R.T. Abraham Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling Curr. Opin. Immunol. 10 3 1998 330 336
2. M. Hidalgo, and E.K. Rowinsky The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 56 2000 6680 6686
3. E.K. Rowinsky Targeting the molecular target of rapamycin (mTOR) Curr. Opin. Oncol. 16 6 2004 564 575
4. N. Sonenberg, and A.C. Gingras The mRNA 5′ cap-binding protein eIF4E and control of cell growth Curr. Opin. Cell Biol. 10 2 1998 268 275
5. N. Pullen, and G. Thomas The modular phosphorylation and activation of p70s6k FEBS Lett. 410 1 1997 78 82
6. S. Chan Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer Br. J. Cancer 91 8 2004 1420 1424
7. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 5573 2002 1655 1657
8. J.R. Testa, and A. Bellacosa AKT plays a central role in tumorigenesis Proc. Natl. Acad. Sci. U. S. A. 98 20 2001 10983 10985
9. D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, and A.K. Godwin AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth Oncogene 23 34 2004 5853 5857
10. I.G. Campbell, S.E. Russell, D.Y. Choong, K.G. Montgomery, M.L. Ciavarella, and C.S. Hooi Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res. 64 21 2004 7678 7681
11. S.A. Stewart, and R.A. Weinberg Telomerase and human tumorigenesis Semin. Cancer Biol. 10 6 2000 399 406
12. Y.S. Cong, W.E. Wright, and J.W. Shay Human telomerase and its regulation Microbiol. Mol. Biol. Rev. 66 3 2002 407 425
13. Y. Yokoyama, Y. Takahashi, A. Shinohara, Z. Lian, and T. Tamaya Telomerase activity in the female reproductive tract and neoplasms Gynecol. Oncol. 68 2 1998 145 149
14. P.S. Zheng, T. Iwasaka, F. Yamasaki, M. Ouchida, M. Yokoyama, and Y. Nakao Telomerase activity in gynecologic tumors Gynecol. Oncol. 64 1 1997 171 175
15. M. Takakura, S. Kyo, T. Kanaya, M. Tanaka, and M. Inoue Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer Cancer Res. 58 7 1998 1558 1561
16. K. Nakano, E. Watney, and J.K. McDougall Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer Am. J. Pathol. 153 3 1998 857 864
17. A. Widschwendter, H.M. Muller, M.M. Hubalek, A. Wiedemair, H. Fiegl, and G. Goebel Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer Gynecol. Oncol. 93 2 2004 407 416
18. G.B. Wisman, A.J. Knol, M.N. Helder, M. Krans, E.G. de Vries, and H. Hollema Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer Int. J. Cancer 91 5 2001 658 664
19. T.W. Park, S. Riethdorf, L. Riethdorf, T. Loning, and F. Janicke Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors Int. J. Cancer 84 4 1999 426 431
20. S. Kyo, T. Kanaya, M. Takakura, M. Tanaka, A. Yamashita, and H. Inoue Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors Int. J. Cancer 80 6 1999 804 809
21. F. Buttitta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, and L. Felicioni Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma J. Clin. Oncol. 21 7 2003 1320 1325
22. A. Kimura, M. Ohmichi, J. Kawagoe, S. Kyo, S. Mabuchi, and T. Takahashi Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines Oncogene 23 26 2004 4505 4515
23. I. Bieche, C. Nogues, V. Paradis, M. Olivi, P. Bedossa, and R. Lidereau Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay Clin. Cancer Res. 6 2 2000 452 459
24. K. Podsypanina, R.T. Lee, C. Politis, I. Hennessy, A. Crane, and J. Puc An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc. Natl. Acad. Sci. U. S. A. 98 18 2001 10320 10325
25. Y. Shi, J. Gera, L. Hu, J.H. Hsu, R. Bookstein, and W. Li Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 Cancer Res. 62 17 2002 5027 5034
26. V. Grunwald, L. DeGraffenried, D. Russel, W.E. Friedrichs, R.B. Ray, and M. Hidalgo Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells Cancer Res. 62 21 2002 6141 6145
27. M.S. Neshat, I.K. Mellinghoff, C. Tran, B. Stiles, G. Thomas, and R. Petersen Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc. Natl. Acad. Sci. U. S. A. 98 18 2001 10314 10319
28. H.B. Jefferies, S. Fumagalli, P.B. Dennis, C. Reinhard, R.B. Pearson, and G. Thomas Rapamycin suppresses 5′ TOP mRNA translation through inhibition of p70s6k EMBO J. 16 12 1997 3693 3704
29. C. Zhou, P.A. Gehrig, Y.E. Whang, and J.F. Boggess Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells Mol. Cancer Ther. 2 8 2003 789 795
30. X. Zhu, R. Kumar, M. Mandal, N. Sharma, H.W. Sharma, and U. Dhingra Cell cycle-dependent modulation of telomerase activity in tumor cells Proc. Natl. Acad. Sci. U. S. A. 93 12 1996 6091 6095
31. S.E. Holt, D.L. Aisner, J.W. Shay, and W.E. Wright Lack of cell cycle regulation of telomerase activity in human cells Proc. Natl. Acad. Sci. U. S. A. 94 20 1997 10687 10692
32. C.C. Hudson, M. Liu, G.G. Chiang, D.M. Otterness, D.C. Loomis, and F. Kaper Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin Mol. Cell. Biol. 22 20 2002 7004 7014
33. D. Bruemmer, F. Yin, J. Liu, T. Kiyono, E. Fleck, and A.J. Van Herle Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells Biochem. Biophys. Res. Commun. 303 1 2003 251 258
34. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev. 18 16 2004 1926 1945
35. S. Hashemolhosseini, Y. Nagamine, S.J. Morley, S. Desrivieres, L. Mercep, and S. Ferrari Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability J. Biol. Chem. 273 23 1998 14424 14429
36. K. Kurose, X.P. Zhou, T. Araki, S.A. Cannistra, E.R. Maher, and C. Eng Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas Am. J. Pathol. 158 6 2001 2097 2106
37. T.H. Cheung, K.W. Lo, S.F. Yim, L.K. Chan, M.S. Heung, and C.S. Chan Epigenetic and genetic alternation of PTEN in cervical neoplasm Gynecol. Oncol. 93 3 2004 621 627
38. K. Yu, L. Toral-Barza, C. Discafani, W.G. Zhang, J. Skotnicki, and P. Frost mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr. Relat. Cancer 8 3 2001 249 258